References
- Carde P., MacKintosh F. R., Rosenberg S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J. Clin. Oncol. 1983; 1: 146–153
- Crawford J., Ozer H., Stroller R., et al. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N. Engl. J. Med. 1991; 325: 164–170
- Pettengel R., Gurney H., Radford J. A., et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non Hodgkin's lymphoma: A randomised controlled trial. Blood 1992; 80: 1430–1436
- Begley C. G., Nicola N. A., Metcalf D. Proliferation of normal human promyelocytes and myelocytes after a single pulse stimulation by purified GM-CSF or G-CSF. Blood 1988; 71: 640–645
- Bonadonna G., Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treatment Reviews 1982; 9: 21–35
- Cannellos G. P., Anderson R., Propert K., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N. Engl. J. Med. 1992; 327: 1478–1484
- Connors J. Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, personal communication